Experimental chlamydia vaccine trial yields encouraging results
The chlamydia vaccine candidate CTH522 shows therapeutic potential in a phase I trial, being safe and well tolerated when adjuvanted with either CAF01 liposomes or aluminium hydroxide. Both vaccine formulations induce anti-CTH522 IgG seroconversion, although CTH522:CAF01 has a better immunogenicity profile.